Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-Infected diabetic foot

International Journal of Lower Extremity Wounds

Volumn 13, Issue 1, 2014, Pages 12-16

  Ambrosch, Andreas ^a,b   Halevy, Daniel ^c   Fwity, Boushra ^b   Brin, Thomas ^b   Lobmann, Ralf ^c  

^a Barmherzige Brüder Hospital   (Germany)

^b Klinikum Stuttgart Burgerhospital   (Germany)

^c StJoseph Hospital Bremerhaven   (Germany)

Author keywords

daptomycin; diabetic foot; MMP 9; MRSA; TIMP 1

Indexed keywords

DAPTOMYCIN; GELATINASE B; INTERLEUKIN 6; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; DIABETIC FOOT; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WOUND FLUID; WOUND HEALING; ADOLESCENT; ADULT; AGED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; ISOLATION AND PURIFICATION; MALE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VERY ELDERLY; WOUND INFECTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; DAPTOMYCIN; DIABETIC FOOT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; WOUND HEALING; WOUND INFECTION; YOUNG ADULT;

EID: 84898961519     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/1534734614523126     Document Type: Article

References (29)

1. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalized patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia. 2010 ; 53: 914-923
2. Richard JL, Sotto A, Jourdan N, et al. Risk factors and healing impact of multidrug resistant bacteria in diabetic foot ulcers. Diabetes Metab. 2008 ; 34: 363-369
3. Ramakant P, Verma AK, Misra R, et al. Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose. Diabetologia. 2011 ; 54: 58-64
4. Sader HS, Fey FD, Limaye AP, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine US medical centers from 2002-2006. Antimicrob Agents Chemother. 2009 ; 53: 4127-4132
5. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. 2007 ; 60: 819-823 (Pubitemid 47434261)
6. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin/amoxicillin-clavulanate. Clin Infect Dis. 2004 ; 38: 17-24 (Pubitemid 38045868)
7. French GL. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J Antimicrob Chemother. 2006 ; 58: 1107-1117 (Pubitemid 44884127)
8. Lobmann R, Schultz G, Lehnert H. Proteases and diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care. 2006 ; 28: 461-471
9. The official standardized wound information sheet from the Diabetic Foot Working Group of the German Diabetic Society. http://www.ag-fuss-ddg.de
10. Barro C, Romaner JP, Fdili A, Guillot M, Morel F. Gelatinase concentration in tears of corneal-grafted patients. Curr Eye Res. 1998 ; 17: 174-182 (Pubitemid 28073783)
11. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res Clin Pract. 2008 ; 80: 344-351
12. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med. 1999 ; 16: 767-771 (Pubitemid 29459276)
13. Richard JL, Sotto A, Jourdan N, et al. Risk factors and healing impact of multidrug resistant bacteria in diabetic foot ulcers. Diabetes Metab. 2008 ; 34: 363-369
14. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000 ; 8: 13-25 (Pubitemid 30140796)
15. Wallace HJ, Stacey MC. Levels of tumor necrosis factor alpha (TNF-?) and soluble TNF receptors in chronic venous leg ulcers - correlations to healing status. J Invest Dermatol. 1998 ; 110: 292-296 (Pubitemid 28144608)
16. Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Kelman I. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastases activity and diminished levels of proteinase inhibitors. Wound Repair Regen. 1997 ; 5: 23-32 (Pubitemid 127686717)
17. Schmohl M, Beckert S, Joos T, Konigsrainer A, Schneiderhahn-Marra N, Löffler M. Superficial wound swabbing: a novel method of sampling and processing wound fluid for subsequent immunoassay analysis in diabetic foot ulceration. Diabetes Care. 2012 ; 35: 2113-2120
18. Fluit AC, Schmitzu FJ, Verhoef J, Milatovic D. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistant determinants. Antimicrob Agents Chemother. 2004 ; 48: 1007-1011 (Pubitemid 38280356)
19. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. J Antimicrob Chemother. 2004 ; 53: 669-674 (Pubitemid 38499788)
20. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005 ; 55: 240-245 (Pubitemid 40331152)
21. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004 ; 38: 1673-1681 (Pubitemid 38781657)
22. Ambrosch A, Lobmann R, Pott A, Preißler J. IL-6 concentrations rather than serological markers are useful in assessing bacterial triggers of ulcer inflammation. Int Wound J. 2008 ; 5: 99-106 (Pubitemid 351379724)
23. Dinh T, Tecilazich F, Kafanas A, et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 2012 ; 61: 2937-2947
24. Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with protease absorbent dressing. J Diabetes Complications. 2006 ; 20: 329-335 (Pubitemid 44308585)
25. Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schieweck S, Lehnert H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia. 2002 ; 45: 26-37
26. Vaalamo M, Weckroth M, Puolakkainen P, et al. Patterns of matrix metalloproteinases and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol. 1996 ; 135: 52-59 (Pubitemid 26225115)
27. Liu Y, Min D, Bolton T, et al. Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care. 2009 ; 32: 117-119
28. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005 ; 366: 1736-1743 (Pubitemid 41587454)
29. Kessler L, Piemont Y, Ortega F, et al. Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis. Diabet Med. 2006 ; 23: 99-102